Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

A legfontosabb adatok

Ki végzi
Arcturus Therapeutics, Inc.
Hol
Ausztrália, Costa Rica, Fülöp-szigetek és Honduras29 helyszín, 4 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
1514 fő vett részt
Kezdés
2024. márc. 27.
Befejezés
2024. nov. 21.
A vizsgálat típusa
Beavatkozással járó, 6 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • ARCT-2303
  • Influenza vaccine
  • Influenza vaccine, adjuvanted
  • Placebo
A regiszteradat frissítve
2025. december 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • 1, Individuals are male, female, or transgender adults ≥18 years of age
  • Healthy participants or participants with pre-existing stable medical conditions
  • Participant or legally authorized representatives must freely provide documented informed consent prior to study procedures being performed
  • Individuals must have been previously vaccinated with COVID-19 vaccines
  • Individuals of childbearing potential must be willing to adhere to contraceptive requirements

Ki nem vehet részt

  • Individuals who have received immunomodulatory, immunostimulatory, or immunosuppressant drugs within 3 months of Screening; or individuals requiring systemic corticosteroids exceeding 10 mg/day of prednisone equivalent for ≥10 days within 30 days of Screening
  • Individuals who have received immunoglobulins and/or any blood or blood products within the 3 months before the first vaccine administration or plan to receive such products at any time during the study
  • Individuals receiving treatment with another investigational drug, biological agent, or device
  • Individuals who have received any investigational COVID-19 vaccines
  • Individuals who received any influenza vaccine within 6 months prior to enrollment or plan to receive an influenza vaccine during the study period
  • Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 14 days after the study vaccination
  • Individuals who are investigator site staff members, employees of the Sponsor or the Clinical Research Organization directly involved in the conduct of the study, or site staff members otherwise supervised by the investigator or immediate family members of any of the previously mentioned individuals
  • Individuals with acute medical illness or febrile illness
  • Individuals with a history of COVID-19 or virologically confirmed SARS-CoV-2 infection within the past 5 months or history of COVID-19 with ongoing sequelae
  • Individuals with a known history of severe hypersensitivity reactions, including anaphylaxis, or other significant adverse reactions to any components of mRNA vaccine, or influenza vaccine, including egg protein
  • Individuals with a history of myocarditis, pericarditis, myopericarditis or cardiomyopathy
  • Individuals with a history of Guillain-Barré syndrome, encephalomyelitis, or transverse myelitis
  • Individuals with a history of congenital or acquired immunodeficiency
  • Individuals with a documented history of HIV infection, or who are currently known to have active tuberculosis
  • Individuals with a positive SARS-CoV-2 rapid antigen test at Screening
  • Individuals who have a positive pregnancy test at the Screening visit or who intend to become pregnant or breastfeed during the study

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered concomitantly with quadrivalent influenza vaccines or standalone in adults who previously received authorized COVID-19 vaccine.

A vizsgálat 6 csoportja

  • Group 1a (ARCT-2303/Influenza vaccine)A vizsgált kezelés

    Participants will receive one 0.5-mL IM (intramuscular) dose of ARCT-2303 and one 0.5-mL IM dose of influenza vaccine on Day 1 followed by a 0.5-mL IM dose of placebo on Day 29.

    Kezelés: ARCT-2303, Influenza vaccine és Placebo

  • Group 2a (ARCT-2303)A vizsgált kezelés

    Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of influenza vaccine on Day 29.

    Kezelés: ARCT-2303, Influenza vaccine és Placebo

  • Group 3a (Influenza vaccine)Már használt kezelés, összehasonlításként

    Participants will receive one 0.5-mL IM dose of influenza vaccine and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of ARCT-2303 on Day 29.

    Kezelés: ARCT-2303, Influenza vaccine és Placebo

  • Group 1b (ARCT-2303/ Influenza vaccine)A vizsgált kezelés

    Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of influenza vaccine on Day 1 followed by a 0.5-mL IM dose of placebo on Day 29.

    Kezelés: ARCT-2303, Influenza vaccine, adjuvanted és Placebo

  • Group 2b (ARCT-2303)A vizsgált kezelés

    Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of influenza vaccine on Day 29.

    Kezelés: ARCT-2303, Influenza vaccine, adjuvanted és Placebo

  • Group 3b (Influenza vaccine)Már használt kezelés, összehasonlításként

    Participants will receive one 0.5-mL IM dose of influenza vaccine and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of ARCT-2303 on Day 29.

    Kezelés: ARCT-2303, Influenza vaccine, adjuvanted és Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Multicenter, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of a Self-Amplifying RNA COVID-19 Vaccine (ARCT-2303), Administered Concomitantly With Quadrivalent Influenza Vaccines, in Adults
Publikációk
A regiszteradat frissítve
2025. december 12.